(IN BRIEF) Sanofi has secured European Commission approval for Sarclisa® subcutaneous administration in combination with standard-of-care regimens for multiple myeloma, covering all indications already approved for the intravenous version of the therapy in the EU. The approval makes Sarclisa the … Read the full press release
